These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27194917)

  • 1. Genetics of Lafora progressive myoclonic epilepsy: current perspectives.
    Kecmanović M; Keckarević-Marković M; Keckarević D; Stevanović G; Jović N; Romac S
    Appl Clin Genet; 2016; 9():49-53. PubMed ID: 27194917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lafora Disease: A Ubiquitination-Related Pathology.
    García-Gimeno MA; Knecht E; Sanz P
    Cells; 2018 Jul; 7(8):. PubMed ID: 30050012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase.
    Liu Y; Zeng L; Ma K; Baba O; Zheng P; Liu Y; Wang Y
    Mol Neurobiol; 2014 Apr; 49(2):645-57. PubMed ID: 24068615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
    Lohi H; Ianzano L; Zhao XC; Chan EM; Turnbull J; Scherer SW; Ackerley CA; Minassian BA
    Hum Mol Genet; 2005 Sep; 14(18):2727-36. PubMed ID: 16115820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lafora disease: Current biology and therapeutic approaches.
    Mitra S; Gumusgoz E; Minassian BA
    Rev Neurol (Paris); 2022 Apr; 178(4):315-325. PubMed ID: 34301405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycogen hyperphosphorylation underlies lafora body formation.
    Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
    Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laforin in autophagy: a possible link between carbohydrate and protein in Lafora disease?
    Puri R; Ganesh S
    Autophagy; 2010 Nov; 6(8):1229-31. PubMed ID: 20818153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
    Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA
    EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired malin expression and interaction with partner proteins in Lafora disease.
    Skurat AV; Segvich DM; Contreras CJ; Hu YC; Hurley TD; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2024 May; 300(5):107271. PubMed ID: 38588813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGK1 (glucose transport), dishevelled2 (wnt signaling), LC3/p62 (autophagy) and p53 (apoptosis) proteins are unaltered in Lafora disease.
    Wang P; Israelian L; Xue Y; Song S; Attisano L; Minassian BA
    All Results J Biol; 2016; 7(3):28-33. PubMed ID: 29152446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes Mellitus in a Patient With Lafora Disease: Possible Links With Pancreatic β-Cell Dysfunction and Insulin Resistance.
    Nicolescu RC; Al-Khawaga S; Minassian BA; Hussain K
    Front Pediatr; 2018; 6():424. PubMed ID: 30701169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy.
    Mitra S; Chen B; Wang P; Chown EE; Dear M; Guisso DR; Mariam U; Wu J; Gumusgoz E; Minassian BA
    Dis Model Mech; 2023 Jan; 16(1):. PubMed ID: 36511140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lafora progressive myoclonus epilepsy: recent insights into cell degeneration.
    Spuch C; Ortolano S; Navarro C
    Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):99-107. PubMed ID: 22369717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of laforin or malin results in increased Drp1 level and concomitant mitochondrial fragmentation in Lafora disease mouse models.
    Upadhyay M; Agarwal S; Bhadauriya P; Ganesh S
    Neurobiol Dis; 2017 Apr; 100():39-51. PubMed ID: 28063983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.